Literature DB >> 19153079

Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion.

Sutep Jaruratanasirikul1, Teeratad Sudsai.   

Abstract

OBJECTIVES: The aim of this study was to compare the t > MICs of imipenem between administration by a 2 h infusion with a 0.5 h infusion.
METHODS: The study was a randomized three-way crossover in nine patients with ventilator-associated pneumonia. Each subject received imipenem in three regimens consecutively: (i) a 0.5 h infusion of 0.5 g every 6 h for 24 h; (ii) a 2 h infusion of 0.5 g every 6 h for 24 h; and (iii) a 2 h infusion of 1 g every 6 h for 24 h.
RESULTS: Following the 0.5 h infusion of 0.5 g of imipenem, the percentages of the t > 4 x MICs of 4, 2 and 1 mg/L were 20.32 +/- 9.32%, 44.11 +/- 16.40% and 64.67 +/- 20.56% of a 6 h interval, respectively. For the 2 h infusion of 0.5 g of imipenem, the percentages of the t > 4 x MICs of 4, 2 and 1 mg/L were 17.71 +/- 19.27%, 53.75 +/- 19.30% and 76.54 +/- 17.36% of a 6 h interval, respectively. For the 2 h infusion of 1 g of imipenem, the percentages of the t > 4 x MICs of 4, 2 and 1 mg/L were 60.26 +/- 23.96%, 77.78 +/- 20.11% and 93.35 +/- 8.26% of a 6 h interval, respectively.
CONCLUSIONS: The 2 h infusions of imipenem resulted in greater t > MICs than the 0.5 h infusion. For infections caused by pathogens with high MICs, a 2 h infusion of 1 g of imipenem every 6 h can provide plasma concentrations above the MIC of 4 mg/L for 60% of a 6 h interval.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19153079     DOI: 10.1093/jac/dkn543

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.

Authors:  Camille Couffignal; Olivier Pajot; Cédric Laouénan; Charles Burdet; Arnaud Foucrier; Michel Wolff; Laurence Armand-Lefevre; France Mentré; Laurent Massias
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

2.  Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility.

Authors:  Andrea Endimiani; Federico Perez; Saralee Bajaksouzian; Anne R Windau; Caryn E Good; Yuvraj Choudhary; Andrea M Hujer; Christopher R Bethel; Robert A Bonomo; Michael R Jacobs
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

3.  Effectiveness and Nephrotoxicity of Loading Dose Colistin-Meropenem versus Loading Dose Colistin-Imipenem in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infection.

Authors:  Wasan Katip; Peninnah Oberdorfer; Nongyao Kasatpibal
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

Review 4.  Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections.

Authors:  Jennifer Shiu; Erica Wang; Aaron M Tejani; Michael Wasdell
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

Review 5.  Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.

Authors:  Joao Gonçalves-Pereira; Pedro Póvoa
Journal:  Crit Care       Date:  2011-09-13       Impact factor: 9.097

6.  Mutant prevention concentrations of imipenem and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  E Dahdouh; S H Shoucair; S E Salem; Z Daoud
Journal:  ScientificWorldJournal       Date:  2014-12-30

7.  Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients.

Authors:  Femke de Velde; Brenda C M de Winter; Michael N Neely; Jan Strojil; Walter M Yamada; Stephan Harbarth; Angela Huttner; Teun van Gelder; Birgit C P Koch; Anouk E Muller
Journal:  Pharmaceutics       Date:  2021-12-16       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.